Biocon Past Earnings Performance
Past criteria checks 4/6
Biocon's earnings have been declining at an average annual rate of -7.7%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 19.3% per year. Biocon's return on equity is 6.1%, and it has net margins of 8.2%.
Key information
-7.7%
Earnings growth rate
-8.0%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | 19.3% |
| Return on equity | 6.1% |
| Net Margin | 8.2% |
| Next Earnings Update | 16 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biocon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 146,125 | 12,002 | 26,439 | -119 |
| 30 Sep 23 | 135,999 | 4,984 | 24,819 | -1,238 |
| 30 Jun 23 | 124,573 | 4,197 | 23,998 | -2,156 |
| 31 Mar 23 | 111,742 | 4,627 | 23,331 | -3,922 |
| 31 Dec 22 | 98,091 | 3,881 | 22,558 | -5,606 |
| 30 Sep 22 | 90,422 | 6,170 | 21,920 | -5,825 |
| 30 Jun 22 | 85,629 | 7,084 | 21,305 | -5,768 |
| 31 Mar 22 | 81,840 | 6,484 | 20,539 | -4,764 |
| 31 Dec 21 | 75,800 | 6,727 | 20,252 | -4,050 |
| 30 Sep 21 | 72,632 | 6,542 | 19,935 | -3,581 |
| 30 Jun 21 | 71,726 | 6,852 | 19,466 | -3,530 |
| 31 Mar 21 | 71,431 | 7,405 | 17,485 | -3,507 |
| 31 Dec 20 | 68,913 | 5,996 | 16,778 | -3,607 |
| 30 Sep 20 | 67,571 | 6,362 | 15,906 | -3,596 |
| 30 Jun 20 | 65,796 | 6,870 | 15,120 | -3,568 |
| 31 Mar 20 | 63,005 | 7,771 | 16,545 | -3,458 |
| 31 Dec 19 | 63,150 | 8,385 | 13,910 | -3,001 |
| 30 Sep 19 | 61,077 | 8,529 | 13,093 | -2,746 |
| 30 Jun 19 | 58,565 | 9,919 | 12,449 | -2,757 |
| 31 Mar 19 | 55,144 | 9,053 | 11,653 | -2,699 |
| 31 Dec 18 | 51,551 | 8,220 | 11,087 | -2,421 |
| 30 Sep 18 | 46,722 | 6,967 | 10,496 | -2,449 |
| 30 Jun 18 | 43,198 | 4,108 | 9,862 | -1,993 |
| 31 Mar 18 | 41,234 | 3,724 | 9,311 | -1,747 |
| 31 Dec 17 | 38,792 | 3,695 | 8,708 | -1,522 |
| 30 Sep 17 | 38,589 | 4,489 | 8,297 | -1,257 |
| 30 Jun 17 | 38,361 | 5,268 | 7,846 | -1,324 |
| 31 Mar 17 | 38,911 | 6,121 | 7,510 | -1,283 |
| 31 Dec 16 | 40,487 | 11,633 | 7,458 | -1,472 |
| 30 Sep 16 | 38,110 | 10,961 | 7,038 | -1,468 |
| 30 Jun 16 | 36,539 | 9,388 | 6,665 | -1,378 |
| 31 Mar 16 | 33,474 | 5,504 | 6,128 | -1,320 |
| 31 Dec 15 | 32,997 | 7,367 | 8,595 | -202 |
| 30 Sep 15 | 32,325 | 7,247 | 8,366 | -196 |
| 30 Jun 15 | 31,528 | 5,207 | 8,223 | -272 |
| 31 Mar 15 | 30,898 | 4,974 | 5,371 | -1,321 |
| 31 Dec 14 | 29,807 | 4,091 | 7,565 | -386 |
| 30 Sep 14 | 29,168 | 4,231 | 7,360 | -561 |
| 30 Jun 14 | 29,014 | 4,232 | 7,137 | -585 |
| 31 Mar 14 | 28,773 | 4,138 | 7,035 | -642 |
| 31 Dec 13 | 28,180 | 5,493 | 6,636 | 47 |
| 30 Sep 13 | 27,510 | 5,361 | 6,428 | 47 |
| 30 Jun 13 | 26,083 | 5,229 | 6,232 | 47 |
Quality Earnings: 532523 has high quality earnings.
Growing Profit Margin: 532523's current net profit margins (8.2%) are higher than last year (4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532523's earnings have declined by 7.7% per year over the past 5 years.
Accelerating Growth: 532523's earnings growth over the past year (209.3%) exceeds its 5-year average (-7.7% per year).
Earnings vs Industry: 532523 earnings growth over the past year (209.3%) exceeded the Biotechs industry -2%.
Return on Equity
High ROE: 532523's Return on Equity (6.1%) is considered low.